Subscribe To
Bridgebio presents detailed positive results from phase 3 attribute-cm study of acoramidis for patients with transthyretin amyloid cardiomyopathy (attr-cm) at european society of cardiology congress 2
– The primary endpoint was met (Win Ratio of 1.8) with a highly statistically significant p-value (p<0.0001); this primary endpoint result consisten...
August 27, 2023, 10:15 am
Bridgebio presents detailed positive results from phase 3 attribute-cm study of acoramidis for patients with transthyretin amyloid cardiomyopathy (attr-cm) at european society of cardiology congress 2
– The primary endpoint was met (Win Ratio of 1.8) with a highly statistically significant p-value (p<0.0001); this primary endpoint result consisten...
August 27, 2023, 10:15 am
Bridgebio presents detailed positive results from phase 3 attribute-cm study of acoramidis for patients with transthyretin amyloid cardiomyopathy (attr-cm) at european society of cardiology congress 2
– The primary endpoint was met (Win Ratio of 1.8) with a highly statistically significant p-value (p<0.0001); this primary endpoint result consisten...
August 27, 2023, 10:15 am
Bridgebio presents detailed positive results from phase 3 attribute-cm study of acoramidis for patients with transthyretin amyloid cardiomyopathy (attr-cm) at european society of cardiology congress 2
– The primary endpoint was met (Win Ratio of 1.8) with a highly statistically significant p-value (p<0.0001); this primary endpoint result consisten...
August 27, 2023, 10:15 am
Scholar rock: the market isn't enthusiastic despite decent clinical data
Scholar Rock Holding Corp. is developing a growth factor targeted therapy called apitegromab for Spinal Muscular Atrophy. Positive interim data from a...
August 27, 2023, 9:13 am
Exelixis: positive pancreatic cancer data brings 2 big catalysts on deck
phase 3 CABINET study, using CABOMETYX to treat patients with advanced pancreatic cancer and advanced p...
August 27, 2023, 6:03 am
Bitcoin spark: solana’s strongest competitor in the crypto arena
Read our article & learn about Solana’s strongest competitor in the crypto market, Bitcoin Spark (BTCS), which is in its presale ...
August 26, 2023, 5:29 pm
Beyond tesla: 3 electric vehicle stocks you've probably overlooked
Automakers around the world are working overtime to pivot to electric vehicles and phase out gasoline-p...
August 26, 2023, 10:00 am
Biomerica reports fiscal 2023 year end results
Revenues excluding Covid test sales increased 15% for fiscal 2023 vs fiscal 2022 Successfully completed inFoods® IBS pilot program with one of the la...
August 25, 2023, 9:00 pm
Neurocrine needs a meaningful clinical win to break out, and crinecerfont could do it
Neurocrine Biosciences needs a clinical win after years of disappointing results and stagnant stock performance. The upcoming ...
August 25, 2023, 6:01 pm
Evelo biosciences: may be worth a small, highly speculative long position considering upcoming psoriasis phase 2 results
Following recent cash raise, EVLO has enough (barely) cash to the next catalyst, phase 2 readout in pso...
August 25, 2023, 5:08 pm
Werewolf: q4 2023 data readout and enhancement of validated targets
Preliminary safety and biomarker results from the phase 1/1b study, using WTX-124 for the treatment of ...
August 25, 2023, 4:48 pm
Exelixis (exel) late-stage study in pancreatic tumors positive
Exelixis' (EXEL) phase III CABINET study shows dramatic improvement in efficacy in advanced pancreatic ...
August 25, 2023, 1:32 pm
Usdjpy daily analysis – august 25, 2023
USDJPY continues to be entrenched in an uptrend that began at 138.05, with the recent price movements from 146.55 appearing to be a consolidation
August 25, 2023, 11:19 am
Merck and eisai cull late-stage study for head and neck cancer therapy
Merck & Co Inc (NYSE:MRK) and research partner Eisai said they are halting a late-stage trial that used a combination of drugs to treat a type of head...
August 25, 2023, 7:58 am
Travere therapeutics to present abstracts at the society for the study of inborn errors of metabolism annual symposium 2023
SAN DIEGO, Aug. 24, 2023 (GLOBE NEWSWIRE) — Travere Therapeutics, Inc. (NASDAQ: TVTX) today announced that the Company will present clinical data fr...
August 24, 2023, 8:30 pm
Travere therapeutics to present abstracts at the society for the study of inborn errors of metabolism annual symposium 2023
SAN DIEGO, Aug. 24, 2023 (GLOBE NEWSWIRE) -- Travere Therapeutics, Inc. (NASDAQ: TVTX) today announced that the Company will present clinical data fro...
August 24, 2023, 4:30 pm
Bridgebio pharma to present detailed results from the phase 3 attribute study in patients with transthyretin amyloidosis cardiomyopathy (attr-cm) at european society of cardiology (esc) congress 2023
PALO ALTO, Calif., Aug. 24, 2023 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (Nasdaq: BBIO) (“BridgeBio” or the “Company”), a commercial-stage...
August 24, 2023, 4:01 pm
The southport school announces kate haft as director of development
Southport Native to Drive Next phase of Fundraising and Alumni Engagement at School Dedicated to Educat...
August 24, 2023, 3:10 pm
Great lakes (gldd) wins contract for port arthur lng phase 1
With this contract, Great Lakes' (GLDD) backlog and recent pending awardable work now exceed $1 billion....
August 24, 2023, 1:32 pm